Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75208
UPID:
COQ9_HUMAN
Alternative names:
-
Alternative UPACC:
O75208; A8K3L2; Q7L5V7; Q7Z5T6; Q8NBL4; Q9NTJ2; Q9P056
Background:
Ubiquinone biosynthesis protein COQ9, mitochondrial, is a lipid-binding protein crucial for the production of coenzyme Q, also known as ubiquinone. This essential lipid-soluble electron transporter is vital for aerobic cellular respiration, binding phospholipids to facilitate coenzyme Q synthesis.
Therapeutic significance:
Linked to Coenzyme Q10 deficiency, primary, 5, a disorder with diverse manifestations, understanding the role of Ubiquinone biosynthesis protein COQ9 could open doors to potential therapeutic strategies. Targeting COQ9's function may offer new avenues for treating this complex condition.